Biography

Carlos L.  Arteaga, M.D., was appointed Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center in September 2017. He holds the Lisa K. Simmons Distinguished Chair in Comprehensive Oncology and brings translational research and cancer center leadership experience to the Simmons Cancer Center.

He earned his medical degree at the University of Guayaquil in Ecuador and trained in internal medicine and medical oncology at Emory University and the University of Texas Health Science Center San Antonio, respectively. He joined Vanderbilt University in 1989, where he held the Donna S. Hall Chair in Breast Cancer Research and served as Director of the Center for Cancer Targeted Therapies, Director of the Breast Cancer Program, and Associate Director for Translational/Clinical Research at the Vanderbilt-Ingram Cancer Center prior to UT Southwestern.

Dr. Arteaga is an internationally recognized expert in breast cancer with more than 350 publications in the areas of oncogenes and breast tumor initiation and progression, targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. His research is or has been continuously funded by the National Cancer Institute, American Cancer Society (ACS), Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C), Susan G. Komen and Breast Cancer Research foundations, Cancer Prevention Research Institute of Texas, and industry.

His contributions have been published in Nature Medicine, Cancer Cell, Cancer DiscoveryScience Translational MedicineJournal of Clinical OncologyCell Metabolism, Journal of Clinical Investigation, Proceeding of the National Academy of Sciences of the United States of American, and Journal of the National Cancer Institute. 

During his career, he has received several awards, including the American Association for Cancer Research (AACR) Richard & Hinda Rosenthal Award, the ACS Clinical Research Professor Award (2007-2017), the Gianni Bonadonna Award from the American Society of Clinical Oncology (2009), the Brinker Award from the Susan G. Komen Foundation (2011), the Prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation (2015), and the Clinical Investigator Award from the Department of Veteran Affairs. 

Dr. Arteaga is a Fellow of the American Association for the Advancement of Science (2013) and Fellow of the AACR Academy (2015). He is an elected member of the American Society for Clinical Investigation (1998) and the Association of American Physicians (2005). He served on the NCI Board of Scientific Counselors (1999-2004) and NCI Subcommittee A (2004-2008).

Dr. Arteaga also serves on the advisory boards of several academic breast cancer programs, SU2C, Susan G. Komen Foundation, and five NCI-designated cancer centers. Since 2009, he has co-chaired the San Antonio Breast Cancer Symposium. In 2019, he was elected to serve on the Board of Directors of the American Association of Cancer Institutes (AACI). He was elected and served as the 2014-15 President of AACR, the largest cancer research organization in the world.

Education

Medical School
Universidad de Guayaquil, Ecuador (1980)
Residency
Emory University School of Medicine (1984), Internal Medicine
Fellowship
University of Texas Health Science Center, San Antonio (1988), Hematology Oncology

Publications

Featured Publications LegendFeatured Publications

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Mayer IA, Prat A, Egle D, Blau S, Perez Fidalgo JA, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz SA, Garcia Estevez L, van Dam PA, Kümmel S, Mundhenke C, Holmes FA, Babbar N, Charbonnier L, Diaz-Padilla I, Vogl FD, Sellami D, Arteaga CL Clin. Cancer Res. 2019 Feb
Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.
Guerrero-Zotano AL, Arteaga CL Cancer Discov 2019 Feb 9 2 304
Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL Cancer Discov 2019 Feb 9 2 303
Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer.
Kaklamani VG, Richardson AL, Arteaga CL Oncologist 2019 Jan
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.
Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE Jr, Lalani AS, Miller VA, Lanman RB, Grishin NV, Arteaga CL. Clin Cancer Res 2019 25 1 277-289
Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial.
Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, Gonzalez-Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CL Clin. Cancer Res. 2018 Oct
Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
Garrett JT, Chakrabarty A, Arteaga CL Oncotarget 2018 Aug 9 64 32400
TGF-ß signaling promotes tumor vasculature by enhancing the pericyte-endothelium association.
Zonneville J, Safina A, Truskinovsky AM, Arteaga CL, Bakin AV BMC Cancer 2018 Jun 18 1 670
Neratinib: Inching up on the cure rate of HER2+ breast cancer?
Unni N, Sudhan DR, Arteaga CL Clin. Cancer Res. 2018 May
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J Ann. Oncol. 2018 Apr